







CITTADINANZA ATTIVA ONLUS - SEDE NAZIONALE  
VIA CEREA TE 6 - 00183 ROMA  
TEL.: +39 06367181 - FAX: +39 0636718333  
WWW.CITTADINANZA ATTIVA.IT

epidemics and cross border diseases. There is clear added-value to strengthen cooperation among all relevant actors at EU level, including health authorities, vaccine industry, research and innovation, healthcare sector and others. We are here today also to remember the decisive role of the civic society, of the citizens organization and the advocacy group in this challenge.

Are there specific rules of engagement to guarantee their contribution in the European Vaccine Action Plan, in the EU Joint Action for Vaccination?

We strongly invite the EU Commission to adopt this inclusive approach when in coming months will adopt a proposal for a Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases.

And what about across Europe at national level? Are there good practices of cooperation promoted by Institutions as well as by professionals?

I am sure the debate today will help us to better identify a pragmatic way to better address common challenges faced by the EU Member States, and to increase the cooperation with all the stakeholder, civic and patients organizations included.

Before to finish please let me talk a little bit about my country, already mentioned for the increased number of measles.

I come from Italy as well as different panelist today, a country where new law on vaccination was recently introduced (some guests will talk about it later on), and where unfortunately – due the incoming election of the new Parliament next week - the topic of vaccination was also included in the pre-electoral debates with the risk of a political/idealistic not scientific approach about it.

Anyway, be quite, we do not have any intention to bring at EU level any pre-electoral countryside debates, on the contrary we are interested to explore the state of the art on vaccine coverage and immunization policy at EU level and across Europe in order to contribute to promote a multi-stakeholder approach in the challenges of life-course vaccination in EU, so in line with the message sent by the already mentioned initiative led by DG Santé.

Well, my turn is over, I just want to thank in advance all the panelist for their contributions, and a special thanks to Suzanne Wait who accepted the role of moderator today. She is Managing Director at “The Health Policy Partnership”, a London-based health policy research consultancy.

Suzanne has worked on a wide range of topics, including most recently life-course approaches to vaccination, viral hepatitis, oncology, and mental health, so is the right expert to chair today.

Thanks again for the attention. I wish you a fruitful meeting.